Global Strategic Investment Solutions 13F: New $226K Stake in ABT

Global Strategic Investment Solutions disclosed on October 16, 2026, that it took a new position in Abbott Laboratories (NYSE: ABT) by acquiring 2,291 shares worth about $226,402. This reflects the firm's interest in the healthcare giant, which focuses on medical devices and diagnostics.

What Changed in Global Strategic Investment Solutions' Abbott Laboratories Position

The firm opened a new position in Abbott Laboratories, acquiring 2,291 shares. This represents an initial investment as part of their strategy.

Other Institutional Activity in Abbott Laboratories

Several major funds have significant stakes in Abbott Laboratories. Blackrock Inc. holds 152,563,476 shares worth approximately $16 billion, having increased its holdings by 6,876,428 shares, a 4.7% rise. Vanguard Capital Management LLC owns 113,750,994 shares valued at about $11.9 billion, increasing its position by 801,938 shares, or 0.7%. State Street Corporation has 80,926,234 shares worth nearly $8.5 billion, up by 1.7% after adding 1,352,749 shares. Charles Schwab Investment Management, Inc. reported a notable increase, growing its holdings by 14,173,548 shares to 59,674,507 shares, a jump of 31.1%. Lastly, Vanguard Portfolio Management LLC added 1,073,944 shares, lifting its total to 49,017,866 shares, a 2.2% increase.

Abbott Laboratories Stock Up 2.3%

Abbott's stock recently traded around $104.70, which is below its 50-day moving average of $105.93 by about 1.2%. However, it is above its 200-day moving average of $102.91 by 1.7%. The stock is currently 20.7% below its 52-week high of $132.03, while it sits 27.7% above its 52-week low of $81.97. Analysts have a mean price target of $120.72 for the stock, suggesting room for growth.

Recent Earnings

Abbott Laboratories reported trailing twelve-month revenue of approximately $46.6 billion and an EPS of $3.10. The company's revenue growth year over year stands at 13.0%, with a net margin of 11.6% and a return on equity of 10.6%. Abbott's next earnings report is set for October 21, 2026.

Insider Buying and Selling at Abbott Laboratories

Several insiders have made trades recently. John G. Stratton, a director, bought 2,000 shares at an average price of $86.82 for a total of $173,640 on May 7, 2026. In contrast, on August 11, 2026, officer Louis H. Morrone sold 5,850 shares at an average price of $109.83, amounting to $642,506. The CEO, Robert B. Ford, sold 398,832 shares on August 25, 2026, with an estimated value of $46.2 million, while officer John A. McCoy Jr. sold 27 shares at $109.54 on September 2, 2026, for about $2,958.

Analysts Set New Price Targets

On October 16, 2026, TD Cowen reiterated its Buy rating for Abbott Laboratories with a price target of $135. This follows an earlier upgrade from Rothschild & Co on October 2, which raised its target to $127 from $119. Barclays initiated coverage on October 7 with an Overweight rating and a target of $120. The consensus among analysts is a strong buy with a mean price target of $120.72 based on 26 opinions.

About Abbott Laboratories

Abbott Laboratories, based in Abbott Park, Illinois, develops and manufactures a wide range of healthcare products. It operates in four segments: established pharmaceuticals, diagnostics, nutritional products, and medical devices. Recent moves by institutional investors, including Global Strategic Investment Solutions, highlight ongoing interest in Abbott amid its robust earnings growth and comprehensive portfolio.

Bottom Line

Investors should watch for Abbott's upcoming earnings report on October 21, 2026, which may provide further insights into the company's performance. Additionally, the recent filings and insider trades indicate active interest in the stock, reflecting potential investor sentiment as the market changes. Keep in mind that 13F filings are backward-looking: they show holdings as of the end of the reporting quarter and may not represent the fund's current position.